CRBUCaribou Biosciences Inc. Common Stock
Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It offers a genome-editing platform based on novel CRISP…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
 Caribou Biosciences, Inc. (CRBU) Reports Q2 Loss, Lags Revenue Estimates Caribou Biosciences (CRBU) delivered earnings and revenue surprises of +27.27% and -40.04%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Lags Revenue Estimates Intellia Therapeutics (NTLA) delivered earnings and revenue surprises of 0.00% and -47.22%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 Vir Biotechnology, Inc. (VIR) Q2 Earnings and Revenues Miss Estimates Vir Biotechnology (VIR) delivered earnings and revenue surprises of -43.37% and -7.51%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 BMS and Gilead rule in the CAR-T space. Off-the-shelf developers aren’t trying to change that. Rather than going head-to-head with approved CAR-T cell therapies, biotechs like Caribou Biosciences are positioning their drugs to fill unique market gaps. | ||
IInsider Monkey | ||